Under the terms of the agreement, Ajinomoto will acquire Forge Biologics for ~$620M in cash. The deal is subject to closing conditions incl. regulatory clearances and is anticipated to close by the end of Q4’2023
Forge to become a fully integrated subsidiary of Ajinomoto, the purchase price payable to Forge’s shareholder (equity value) is expected to be adjusted at the time of execution, and it is currently estimated to be around ~$554M
Forge is a clinical-stage therapeutics firm that develops and manufactures plasmids and viral vectors, facilitating access to potentially life-changing gene therapies
Ref: Forge Biologics | Image: Forge Biologics
Related News:- Exelixis Entered into a License Agreement with Ajinomoto Co. to Discover and Develop Novel Antibody-Drug Conjugates for Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
